KROS

Over the past six months, Keros Therapeutics experienced several stock-impacting events. In September 2026, the company announced the first patient dosing in the Phase 2 clinical trial for rinvatercept in Duchenne Muscular Dystrophy, which was followed by an expected development milestone payment from its partner Takeda. Also in September 2026, Keros authorized a $5 million share repurchase program. In August 2026, the company reported a Q2 2026 net loss of $28.7 million. Q1 2026 earnings were released in May 2026, and in April 2026, a proxy statement was filed for shareholder voting and corporate governance matters. The stock has shown volatility, with a 52-week high of $22.55 and a low of $9.69, closing at $11.64 on October 8, 2026, representing a 27.1% loss over the past 12 months.